Escitalopram reduces attentional performance in anxious older adults with high-expression genetic variants at serotonin 2A and 1B receptors
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Older adults are among the most vulnerable to adverse cognitive effects of psychotropic medications and, therefore, the personalization of psychotropic treatment based on adverse drug reactions in this demographic is of great importance. We examined changes on neuropsychological tests of attention attributable to selective serotonin reuptake inhibitor (SSRI) treatment in anxious older adults. We also examined whether variation in serotonin receptor genes was associated with reduced attentional performance with SSRIs. We examined change from pre- to post-treatment in two attention measures - digit span and coding - in 133 adults aged ≥60 yr with generalized anxiety disorder in a 12-wk trial of escitalopram vs. placebo. We also examined attentional change in relation to genetic variability in four central serotonin receptors: the serotonin transporter and serotonin 1A, 2A and 1B receptors. Digit span scores were significantly lowered in patients receiving escitalopram relative to placebo, indicating reduced attentional performance attributable to the SSRI. Individuals with high-transcription variants in the receptors 5-HTR2A rs6311 and 5-HTR1B rs11568817 had greater reductions in attention with SSRI treatment compared to placebo. We conclude that SSRIs reduce attention in older adults, particularly in those with high-expression genetic variants at the serotonin 2A and 1B receptors. Analysing neuropsychological changes with SSRIs in relation to genetic variation in the serotonin system may be a useful strategy for detecting subgroups of older adults who are more susceptible to side-effects of SSRIs. These results, if confirmed, could lead to the personalization of SSRI use to reduce adverse neurocognitive effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a human study of elderly subjects with generalized anxiety, citalopram reduced attentional performance compared to placebo; this effect strongly correlated with high-transcription variants of 5-HT2A and 5-HT1B receptors (Lenze et al 2013).”
From Prefrontal cortex executive processes affected by stress in health and disease (2018) · cites this paper as Lenze et al 2013
Experimental — accuracy not yet measuredIn the citing paper
“In a human study of elderly subjects with generalized anxiety, citalopram reduced attentional performance compared to placebo; this effect strongly correlated with high-transcription variants of 5-HT2A and 5-HT1B receptors (Lenze et al 2013).”
From Prefrontal cortex executive processes affected by stress in health and disease (2018) · cites this paper as Lenze et al 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PLINK: a tool set for whole-genome association and population-based linkage analyses.
Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., Maller, J., Sklar, P., de Bakker, P. I. W., Daly, M. J., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/519795 · Cited by 34,089 · cited 1×
“We tested linkage disequilibrium between the three serotonin 1B receptor polymorphisms using PLINK software (http://pngu.mgh.harvard.edu/purcell/ plink/; Purcell et al. 2007).”
MethodHamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 1×
“Severity of symptoms was assessed using the Hamilton scales for depression and anxiety (Hamilton, 1959, 1960) and the Penn State Worry Questionnaire, which measures worry severity (Meyer et al. 1990).”
MethodThe assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455 · cited 4×
“…of GAD (according to the Structured Diagnostic Interview for DSM-IV axis I diagnoses ; First et al. 1996) and a score of o17 on the Hamilton Anxiety Rating Scale (Hamilton, 1959) Subjects were randomized to 10 mg escitalopram (increased to 20 mg after 4 wk if tolerated and as needed) or placebo.”
MethodInfluentialDevelopment and validation of the Penn State Worry Questionnaire
Meyer, T. J., Miller, M. L., Metzger, R. L., & Borkovec, T. D. (1990) · Behaviour Research and Therapy · doi:10.1016/0005-7967(90)90135-6 · Cited by 5,099 · cited 1×
“Severity of symptoms was assessed using the Hamilton scales for depression and anxiety (Hamilton, 1959, 1960) and the Penn State Worry Questionnaire, which measures worry severity (Meyer et al. 1990).”
MethodRandolph, C., Tierney, M. C., Mohr, E., & Chase, T. N. (1998) · Journal of Clinical and Experimental Neuropsychology · doi:10.1076/jcen.20.3.310.823 · Cited by 2,519
National Patterns in Antidepressant Medication Treatment
Olfson, M., & Marcus, S. C. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.81 · Cited by 730 · cited 3×
“Such research could identify genetic subgroups of individuals more likely to suffer neurocognitive side-effects of serotonergic antidepressants, leading to personalization of treatment for the growing number of older adults taking these medications (Olfson & Marcus, 2009 ; Pagura et al. 2011).”
BackgroundWendland, J. R., Martin, B. J., Kruse, M. R., Lesch, K.-P., & Murphy, D. L. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001789 · Cited by 561 · cited 2×
“For the serotonin transporter polymorphisms we followed a protocol that genotypes the SLC6A4 promoter haplotype Downloaded from https://academic.oup.com/ijnp/article-abstract/16/2/279/623445 by guest on 25 July 2018 (Wendland et al. 2006).”
BackgroundMethodMcMahon, F. J., Buervenich, S., Charney, D., Lipsky, R., Rush, A. J., Wilson, A. F., Sorant, A. J. M., Papanicolaou, G. J., Laje, G., Fava, M., et al. (2006) · The American Journal of Human Genetics · doi:10.1086/503820 · Cited by 474 · cited 2×
“To maximize power, we dichotomized subjects within each genotype into ‘high transcription’ or ‘ low transcription’ groups based on the presence or absence of at least one high-transcription allele (Conner et al. 2010; Lemonde et al. 2004; McMahon et al. 2006; Villafuerte et al. 2009; Wilkie et al. 2008).”
MethodMolecular Genetics of Attention Deficit Hyperactivity Disorder
Faraone, S. V., & Mick, E. (2010) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2009.12.004 · Cited by 411
Biederman, J., Krishnan, S., Zhang, Y., McGough, J. J., & Findling, R. L. (2007) · Clinical Therapeutics · doi:10.1016/s0149-2918(07)80083-x · Cited by 404 · cited 3×
“Compared with placebo (18%), CGI-lmprovement (CGI-I) ratings of very much improved or much improved were seen in 2=70% of children receiving LDX.(26) Wigal and colleagues(27) evaluated the efficacy of LDX in 129 school-aged children with ADHD in a 6 week, randomized, double-blind, placebocontrolled, analog classroom c…”
BackgroundInfluential
Research works printed but not linked: 3
- 1992, NONMEM Users Guides
- 1996, Structured Clinical Interview for DSM-IV Axis I Disorders (SCID)
- 1998, Repeatable Battery for the Assessment of Neuropsychological Status Manual
Cited by
Genetics of generalized anxiety disorder and related traits
Gottschalk, M. G., & Domschke, K. (2017) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2017.19.2/kdomschke · Cited by 194
Prefrontal cortex executive processes affected by stress in health and disease
Girotti, M., Adler, S. M., Bulin, S. E., Fucich, E. A., Paredes, D., & Morilak, D. A. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.07.004 · Cited by 176
Anxiety is associated with increased risk of dementia in older Swedish twins
Petkus, A. J., Reynolds, C. A., Wetherell, J. L., Kremen, W. S., Pedersen, N. L., & Gatz, M. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.09.008 · Cited by 101
“Likewise, genes associated with serotonin reuptake and the dopaminergic systems have been implicated with anxiety and cognitive performance [45–47].”
BackgroundAnderson, M. R., Miller, L., WICKRAMARATNE, P. J., Svob, C., Odgerel, Z., Zhao, R., & Weissman, M. M. (2017) · Spirituality in Clinical Practice · doi:10.1037/scp0000125 · Cited by 70
“Both SNPs interact with antidepressant type to show a differential association with side effects such as suicidal ideation as well as response time and efficacy (Lenze et al., 2013; Perroud et al., 2011; Villafuerte et al., 2009; Xu et al., 2012).”
BackgroundGassó, P., Rodríguez, N., Blázquez, A., Monteagudo, A., Boloc, D., Plana, M. T., Lafuente, A., Lázaro, L., Arnáiz, J. A., & Mas, S. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.12.003 · Cited by 43
“Genetic variants inHTR1B have been associated with antidepressant response and certain behavioral traits during antidepressant treatment (Lenze et al., 2013; Perroud et al., 2011).”
Metadata
- Authors
- Lenze, E. J., Dixon, D., Nowotny, P., Lotrich, F. E., Doré, P. M., Pollock, B. G., Hinrichs, A. L., & Butters, M. A.
- Affiliations
- Washington University in St. Louis (US)
- University of Pittsburgh (US)
- Centre for Addiction and Mental Health (CA)
- Corresponding author
- Lenze, Eric J.
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-04-17
- Volume
- 16
- Issue
- 2
- Pages
- 279-288
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC3967864
- OpenAlex
- W2131845222
- Cited by
- 23
- References
- 56
- Citations by year
- 2026: 1 · 2025: 1 · 2023: 2 · 2022: 1 · 2021: 2 · 2020: 1 · 2019: 1 · 2017: 5 · 2016: 2 · 2015: 3 · 2014: 1 · 2013: 3
- FWCI
- 0.92
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- National Institutes of Health (UL1TR000005)
- National Institute of Mental Health (R01MH072947, K23MH074012, R01MH070547)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- escitalopram, selective serotonin reuptake inhibitors, attention, generalized anxiety disorder, older adults, serotonin receptor gene, 5-HT2A receptor, 5-HT1B receptor, 5-HT1A receptor, serotonin transporter, genetic polymorphism, digit span, adverse drug reactions, individualized drug therapy, cognitive side effects
- MeSH terms
- Aged, Aged, 80 and over, Anxiety, Attention, Double-Blind Method, Female, Humans, Male, Middle Aged, Neuropsychological Tests, Surveys and Questionnaires, Retrospective Studies, Time Factors, Citalopram, Selective Serotonin Reuptake Inhibitors, Statistics, Nonparametric, Polymorphism, Single Nucleotide, Receptor, Serotonin, 5-HT1B, Receptor, Serotonin, 5-HT2A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Escitalopram reduces attentional performance in anxious older adults with high-expression genetic variants at serotonin 2A and 1B receptors. https://app.cochat.ai/papers/10.1017/s1461145712000351
- The paper
- Lenze, E. J., Dixon, D., Nowotny, P., Lotrich, F. E., Doré, P. M., Pollock, B. G., Hinrichs, A. L., & Butters, M. A. (2013). Escitalopram reduces attentional performance in anxious older adults with high-expression genetic variants at serotonin 2A and 1B receptors. International Journal of Neuropsychopharmacology. https://doi.org/10.1017/s1461145712000351
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.